Tenax Therapeutics, Inc.
TENX
TENX: Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
moreShow TENX Financials
Recent trades of TENX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by TENX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) Jul. 18, 2023
-
Patent Title: Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) Mar. 21, 2023
-
Patent Title: Pharmaceutical compositions for subcutaneous administration of levosimendan Jan. 04, 2022
Federal grants, loans, and purchases
Followers on TENX's company Twitter account
Number of mentions of TENX in WallStreetBets Daily Discussion
Recent insights relating to TENX
Recent picks made for TENX stock on CNBC
ETFs with the largest estimated holdings in TENX
Flights by private jets registered to TENX